Under the deal, France-based Sanofi SA plans on buying all of the outstanding shares of the Massachusetts-based company's common stock for $105 per... To view the full article, register now.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
Sanofi will begin a tender offer for all of Ablynx’s outstanding shares. The deal is contingent on shareholders tendering at least 75 percent of the stock. Sanofi
U.S. stock futures traded lower on Monday ... maker unveiled a new 5G chipset …
SNY's market value is $114.9 billion which falls in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 29 among the 133 companies in this industry group, placing it among the leaders; in the top quartile of …
All of the foregoing was an obvious breath of fresh air at Sanofi at the time, but it now looks as if the French board has had enough. Bernstein analyst Tim Anderson, the dean of the pharma stock investment community, summed up the …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
NASDAQ8mon
As such, Sanofi and Glaxo appear to be logical suitors for Novavax ... That being said, the current buyout speculation surrounding Novavax is simply not a good reason to buy its stock. A buyout may happen soon. But the more likely …